查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081995

人類微生物組市場：按類型、目標微生物組部位、應用和最終用戶分類－2026-2032年全球市場預測

Human Microbiome Market by Type, Target Microbiome Site, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人類微生物組市場將成長至 114 億美元，複合年成長率為 24.83%。

主要市場統計數據
基準年 2025 24.1億美元
預計年份：2026年 29.8億美元
預測年份 2032 114億美元
複合年成長率 (%) 24.83%

人類微生物組市場簡介

人類微生物組研究已從探索性定定序發展到實證醫學，揭示了腸道、皮膚、口腔、泌尿生殖道和呼吸系統中微生物群落之間的關係及其對免疫、代謝、發炎、神經傳遞和藥物反應的影響。宏基因組鳥槍總體基因體學、代謝體學、多體學整合和菌株層級分析的進步，正在提升我們識別臨床相關微生物功能的能力，而不僅僅依賴分類學相關性。

人類微生物組領域的變革性變化

該領域的趨勢正從益生菌的廣泛定位轉向以總體基因體學、代謝體學、菌株水平分析、標準化終點和受控臨床證據為支撐的機制導向干預。企業越來越重視明確的菌叢組合、後生元、新一代益生菌、微生物組生物標記和標靶生物治療產品，而非泛泛地宣稱其具有促進健康的功效。

人工智慧對微生物組創新的累積影響

人工智慧透過加速微生物組數據的解讀、菌株和功能的繪製、生物標記的發現以及臨床試驗的設計，進一步推動了相關領域的發展。機器學習模型能夠將微生物豐富度、微生物基因、代謝物、宿主基因組、飲食、藥物、生活方式因素和疾病表現型聯繫起來，而傳統統計方法往往很難做到這一點。

人類微生物組市場的關鍵區域洞察

北美在臨床應用領域處於領先地位，這得益於美國國立衛生研究院 (NIH) 資助的微生物組研究、美國食品藥品監督管理局 (FDA) 的生物製藥產品核准途徑、先進的定序能力、大學附屬醫療中心以及創業投資驅動的生物技術活動。該地區擁有強大的主導環境，重點關注臨床試驗、分子診斷、復發性艱難梭菌感染疾病的治療、發炎性腸道疾病研究以及與腫瘤相關的微生物組研究。

針對特定群體的微生物組生長策略的關鍵見解

歐盟和七國集團為基於微生物組的療法、診斷和營養領域的創新提供了堅實的基礎，這得益於其先進的臨床基礎設施、高水準的研究活動、成熟的監管體系和完善的保險報銷評估流程。北約成員國與許多主要的生物醫學市場重疊，促進了跨境研究合作、生產韌性、臨床數據交換、抗菌素抗藥性研究以及與宿主和微生物組科學相關的健康安全應用。

來自影響人類微生物組需求的關鍵國家的見解

美國仍然是微生物組療法、臨床試驗、定序的診斷以及FDA批准產品核可途徑的關鍵市場。同時，加拿大擁有強大的學術研究實力、公共衛生專業知識以及與實證醫療保健標準相符的監管體系。墨西哥和巴西是拉丁美洲益生菌、營養、胃腸病學和微生物組研究的重要市場，這些研究針對不同人群，並受到人們對預防醫學和飲食相關代謝疾病日益成長的興趣的推動。

為人類微生物組領域的領導者提供的實用建議

產業領導企業應優先考慮經臨床檢驗的適應症、差異化的作用機制以及已準備好提交監管部門的證據資料。最有效的策略是將菌株層級的表徵、標準化的生產流程、基因組和表現型鑑定、安全性文件、穩定性數據以及可供保險公司、臨床醫生和監管機構評估的終點指標相結合。

人類微生物組市場的調查方法。

調查方法建立在經過驗證的二手研究之上，包括監管公告、臨床試驗註冊資訊、同行評審的微生物組相關文獻、公共衛生機構資源、專利趨勢、產品核可記錄、技術指南以及與醫療保健、生物技術、檢驗和營養相關的宏觀經濟指標。

結論：基於證據的人類微生物組市場成長

人類微生物組市場正進入一個更系統化的階段，更加重視臨床證據、監管細則、人工智慧驅動的分析、檢驗的生物標記以及可擴展的生產，而非泛泛的健康益處宣稱。已通過核准的基於微生物群的複發性艱難梭菌感染疾病療法增強了人們對該領域的信心，並為未來的生物製藥開發樹立了標竿。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：人類微生物組市場：依類型分類

  • 抗生素
  • 診斷設備
    • 微生物組定序設備
    • 基於PCR的診斷方法
  • 益生元
    • 菊糖
    • 寡糖
  • 益生菌
  • 合益素

第8章：人類微生物組市場：依微生物組部位分類

  • 腸道微生物組
  • 鼻腔與呼吸道微生物組
  • 口腔微生物組
  • 皮膚微生物組
  • 陰道微生物組

第9章：人類微生物組市場：依應用分類

  • 診斷
    • 生物標記發現
    • 臨床診斷
    • 伴隨診斷
  • 補充
  • 治療
    • 消化系統疾病
    • 感染疾病
    • 代謝性疾病
    • 皮膚病

第10章：人類微生物組市場：依最終用戶分類

  • 診斷檢查室
  • 居家醫療
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第11章：人類微生物組市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 人類微生物組市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：人類微生物組市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AOBiome, LLC
  • Astarte Medical
  • Axial Therapeutics, Inc.
  • Azitra
  • BioGaia AB
  • BioHM Health Inc.
  • BiomeBank
  • BiomeSense, Inc.
  • BiomX Ltd.
  • DuPont de Nemours, Inc.
  • Enterome Bioscience
  • Exeliom Biosciences SAS
  • Ferring BV
  • Finch Therapeutics Group, Inc.
  • Ginkgo Bioworks, Inc.
  • Illumina, Inc.
  • Infinant Health Inc.
  • International Flavors & Fragrances Inc.
  • Intralytix, Inc.
  • Invivo Healthcare
  • MaaT Pharma
  • Merck KGaA
  • Metabiomics Corporation
  • OptiBiotix Health plc
  • Osel Inc.
  • Pendulum Therapeutics
  • Rebiotix Inc.
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Theriva Biologics, Inc.
  • Viome Life Sciences, Inc.
  • Yakult Honsha Co., Ltd.
Product Code: MRR-430D42AA0FCD

The Human Microbiome Market is projected to grow by USD 11.40 billion at a CAGR of 24.83% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.41 billion
Estimated Year [2026] USD 2.98 billion
Forecast Year [2032] USD 11.40 billion
CAGR (%) 24.83%

Human Microbiome Market Introduction

The human microbiome has moved from exploratory sequencing into evidence-based healthcare, linking microbial communities across the gut, skin, oral cavity, urogenital tract, and respiratory system with immunity, metabolism, inflammation, neurological signaling, and drug response. Advances in shotgun metagenomics, metabolomics, multi-omics integration, and strain-level profiling are improving the ability to identify clinically relevant microbial functions rather than relying only on taxonomic associations.

For industry leaders, the highest-value opportunities are concentrated in microbiome therapeutics, live biotherapeutic products, companion diagnostics, metagenomic testing, probiotics, prebiotics, synbiotics, postbiotics, and precision nutrition. Regulatory milestones, including FDA-approved microbiota-based products for recurrent Clostridioides difficile infection, validate the field's clinical direction and reinforce the need for robust safety, manufacturing, and efficacy evidence.

Transformative Shifts in the Human Microbiome Landscape

The landscape is shifting from broad probiotic positioning to mechanism-led interventions supported by metagenomics, metabolomics, strain-level analytics, standardized endpoints, and controlled clinical evidence. Companies are increasingly prioritizing defined consortia, postbiotics, next-generation probiotics, microbiome biomarkers, and targeted live biotherapeutic products over generalized wellness claims.

Another transformative shift is the convergence of microbiome science with oncology, immunology, gastroenterology, dermatology, metabolic disease, infectious disease, and women's health. Partnerships among biopharma organizations, diagnostics developers, academic centers, hospitals, and contract manufacturers are becoming essential to translate microbial signatures into clinically validated, reimbursable, and scalable healthcare products.

Cumulative Impact of Artificial Intelligence on Microbiome Innovation

Artificial intelligence is compounding progress by accelerating microbiome data interpretation, strain-function mapping, biomarker discovery, and clinical trial design. Machine learning models help connect microbial abundance, microbial genes, metabolites, host genomics, diet, medications, lifestyle factors, and disease phenotypes in ways that traditional statistical approaches often cannot scale.

The cumulative impact is most visible in target identification, patient stratification, formulation optimization, adverse-event surveillance, and longitudinal response monitoring. AI-enabled platforms can improve study efficiency and signal detection, but adoption still depends on transparent models, validated datasets, reproducible findings, privacy protection, bias control, and clinically meaningful endpoints accepted by regulators, clinicians, and payers.

Key Regional Insights Across the Human Microbiome Market

North America leads in clinical translation, supported by NIH-funded microbiome research, FDA pathways for live biotherapeutic products, advanced sequencing capacity, academic medical centers, and venture-backed biotechnology activity. The region's emphasis on clinical trials, molecular diagnostics, recurrent C. difficile infection treatment, inflammatory bowel disease research, and oncology-adjacent microbiome studies supports a strong evidence-generation environment.

Europe remains strong in microbiome regulation, nutrition science, biobanking, and clinical research, while European Union rules on health claims and medical products shape evidence-based product positioning. Asia-Pacific is expanding through China, India, Japan, South Korea, and Australia, where sequencing infrastructure, probiotic consumption, functional food innovation, precision medicine programs, and digital health adoption are advancing microbiome applications.

Latin America, led by Brazil and Mexico, is gaining relevance in nutrition, probiotics, gastroenterology, and population-diverse microbiome studies. The Middle East, especially GCC health systems, is investing in genomics, preventive care, and national precision medicine programs that can support microbiome integration. Africa offers underrepresented microbial diversity and important public health research opportunities, particularly for infectious disease, nutrition, maternal health, and environment-linked microbiome studies.

Key Group Insights for Microbiome Growth Strategies

The European Union and G7 economies provide strong foundations for microbiome therapeutics, diagnostics, and nutrition innovation because of advanced clinical infrastructure, high research intensity, mature regulatory systems, and established reimbursement evaluation processes. NATO economies overlap with many leading biomedical markets, supporting cross-border research collaboration, manufacturing resilience, clinical data exchange, antimicrobial resistance research, and health security applications tied to host-microbiome science.

BRICS countries are becoming increasingly important due to large patient populations, expanding sequencing capacity, rising chronic disease burden, and local biomanufacturing ambitions. ASEAN markets show rising demand for gut health products, preventive care, maternal and infant nutrition, and functional foods, while GCC countries are using genomics, digital health, and precision medicine investments to position microbiome science within national health transformation programs.

Key Country Insights Shaping Human Microbiome Demand

The United States remains the anchor market for microbiome therapeutics, clinical trials, sequencing-based diagnostics, and FDA-recognized product pathways, while Canada contributes strong academic research, public health expertise, and regulatory alignment with evidence-based healthcare standards. Mexico and Brazil are important Latin American markets for probiotics, nutrition, gastroenterology, and population-diverse microbiome studies, supported by growing interest in preventive health and diet-linked metabolic conditions.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine clinical research strength with nutrition science, diagnostics, pharmaceutical capabilities, biobanks, and strong hospital networks; Russia maintains scientific capacity and microbiology expertise despite market-access and geopolitical complexity. Germany and France are particularly relevant for regulated healthcare innovation and nutrition research, while the United Kingdom benefits from genomics infrastructure and translational research networks.

China, India, Japan, Australia, and South Korea are accelerating through sequencing investments, digital health adoption, functional food demand, clinical research, and precision medicine initiatives. China's large-scale genomics capacity, India's expanding biotechnology base, Japan's long-standing probiotic and functional food culture, Australia's clinical research quality, and South Korea's digital health and biopharma capabilities collectively strengthen Asia-Pacific's role in human microbiome innovation.

Actionable Recommendations for Human Microbiome Leaders

Industry leaders should prioritize clinically validated indications, differentiated mechanisms of action, and regulatory-ready evidence packages. The strongest strategies combine strain-level characterization, standardized manufacturing, genomic and phenotypic identity testing, safety documentation, stability data, and endpoints that payers, clinicians, and regulators can evaluate.

Firms should also invest in AI-enabled analytics, longitudinal datasets, biobank partnerships, companion diagnostics, and multi-omics platforms while avoiding unsupported wellness claims. Successful commercialization will depend on medical education, reimbursement planning, quality control for live products, cold-chain and storage validation where required, and partnerships that connect discovery, clinical development, manufacturing, regulatory affairs, and market access.

Research Methodology for Human Microbiome Market Intelligence

Research methodology is built from verified secondary research, including regulatory announcements, clinical trial registries, peer-reviewed microbiome literature, public health agency resources, patent activity, product approval records, technical guidelines, and macroeconomic indicators relevant to healthcare, biotechnology, diagnostics, and nutrition.

Insights were triangulated across product type, application, region, end-user demand, clinical maturity, and regulatory readiness. The methodology emphasizes evidence strength, reproducibility, clinical relevance, safety, manufacturing feasibility, and market applicability, with special attention to microbiome therapeutics, diagnostics, probiotics, prebiotics, synbiotics, postbiotics, sequencing, AI analytics, and live biotherapeutic manufacturing.

Conclusion: Evidence-Based Growth in the Human Microbiome Market

The human microbiome market is entering a more disciplined phase in which clinical proof, regulatory clarity, AI-enabled analysis, validated biomarkers, and scalable manufacturing matter more than broad health claims. Approved microbiota-based therapies for recurrent C. difficile infection have strengthened confidence in the field and created a reference point for future live biotherapeutic development.

Future progress will come from evidence-backed therapeutics, precision diagnostics, functional nutrition, and data platforms that translate complex microbial ecosystems into actionable healthcare decisions. Organizations that combine scientific rigor with commercial discipline, transparent data practices, and regulatory preparedness will be best positioned to lead.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Human Microbiome Market, by Type

  • 7.1. Antibiotics
  • 7.2. Diagnostic Devices
    • 7.2.1. Microbiome Sequencing Devices
    • 7.2.2. PCR-Based Diagnostics
  • 7.3. Prebiotics
    • 7.3.1. Inulin
    • 7.3.2. Oligosaccharides
  • 7.4. Probiotics
  • 7.5. Synbiotics

8. Human Microbiome Market, by Target Microbiome Site

  • 8.1. Gut Microbiome
  • 8.2. Nasal & Respiratory Microbiome
  • 8.3. Oral Microbiome
  • 8.4. Skin Microbiome
  • 8.5. Vaginal Microbiome

9. Human Microbiome Market, by Application

  • 9.1. Diagnostics
    • 9.1.1. Biomarker Discovery
    • 9.1.2. Clinical Diagnostics
    • 9.1.3. Companion Diagnostics
  • 9.2. Supplements
  • 9.3. Therapeutics
    • 9.3.1. Gastrointestinal Disorders
    • 9.3.2. Infections
    • 9.3.3. Metabolic Disorders
    • 9.3.4. Skin Disorders

10. Human Microbiome Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Home Care Settings
  • 10.3. Hospitals & Clinics
  • 10.4. Pharmaceutical & Biotechnology Companies
  • 10.5. Research Institutes

11. Human Microbiome Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Human Microbiome Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Human Microbiome Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AOBiome, LLC
  • 15.2. Astarte Medical
  • 15.3. Axial Therapeutics, Inc.
  • 15.4. Azitra
  • 15.5. BioGaia AB
  • 15.6. BioHM Health Inc.
  • 15.7. BiomeBank
  • 15.8. BiomeSense, Inc.
  • 15.9. BiomX Ltd.
  • 15.10. DuPont de Nemours, Inc.
  • 15.11. Enterome Bioscience
  • 15.12. Exeliom Biosciences SAS
  • 15.13. Ferring B.V.
  • 15.14. Finch Therapeutics Group, Inc.
  • 15.15. Ginkgo Bioworks, Inc.
  • 15.16. Illumina, Inc.
  • 15.17. Infinant Health Inc.
  • 15.18. International Flavors & Fragrances Inc.
  • 15.19. Intralytix, Inc.
  • 15.20. Invivo Healthcare
  • 15.21. MaaT Pharma
  • 15.22. Merck KGaA
  • 15.23. Metabiomics Corporation
  • 15.24. OptiBiotix Health plc
  • 15.25. Osel Inc.
  • 15.26. Pendulum Therapeutics
  • 15.27. Rebiotix Inc.
  • 15.28. Synlogic, Inc.
  • 15.29. Synthetic Biologics, Inc.
  • 15.30. Theriva Biologics, Inc.
  • 15.31. Viome Life Sciences, Inc.
  • 15.32. Yakult Honsha Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN MICROBIOME MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HUMAN MICROBIOME MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HUMAN MICROBIOME MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HUMAN MICROBIOME MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIAGNOSTIC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME SEQUENCING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME SEQUENCING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME SEQUENCING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PCR-BASED DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PCR-BASED DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PCR-BASED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PREBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OLIGOSACCHARIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OLIGOSACCHARIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OLIGOSACCHARIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYNBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYNBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYNBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GUT MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GUT MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GUT MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NASAL & RESPIRATORY MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NASAL & RESPIRATORY MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NASAL & RESPIRATORY MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SKIN MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SKIN MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SKIN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VAGINAL MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VAGINAL MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VAGINAL MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUPPLEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SKIN DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SKIN DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SKIN DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 161. GCC HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 188. G7 HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 190. G7 HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 197. NATO HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 290. SPAIN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 306. INDIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 307. INDIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 308. INDIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. INDIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 310. INDIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 311. INDIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 316. JAPAN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 324. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 325. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 326. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 327. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 328. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 333. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 334. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 335. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 336. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 337. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 338. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)